Inflammation is a complex biological response to potential threats. But sometimes when the immune system is triggered, its fails to resolve, and unwanted damage ensues. Many inflammatory diseases result from a flooding of signals to activate the immune system without adequate off-signals to resolve it. Corbus Pharmaceuticals lead candidate lenabasum targets the immune system off-switch. The company is in late-stage testing of the experimental therapy for the rare condition systemic sclerosis. We spoke to Yuval Cohen, CEO of Corbus, about the workings of the immune system, what lenabasum does, and why it may have use in a broad number of chronic inflammatory and fibrotic conditions.